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• One out of  every eight women will be diagnosed with 
breast cancer in 2011
• Fortunately, radical mastectomy (surgical removal) is rarely 
needed today with better treatment options
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Breast cancer is second only to lung 
cancer as a cause of cancer deaths in American women
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Trends since 1950 in 
age-standardized death 
rates  comparing breast 
and selected other types 
of cancer, among women 
in the USA
EBCTCG, Lancet, 2010
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BREAST CANCER IN THE WORLD
 1.15 million new cases
 Incidence increasing in most countries
 470 000 deaths
 Half  of  the global burden in low- and medium-resourced 
countries
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women are 
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7PTEN is a tumor suppressor gene that is essential for 
embryonic development
 PTEN gene located on Chrom 10 (10q23)
 Several different Pten null mice lines were generated-produced 
varying results depending upon which genetic background of  mouse 
was used (e.g.129SvEv vs. C57Bl6)
 But in all cases mice do NOT survive to birth  PTEN required for 
embryogenesis
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PTEN is a key player in some human diseases
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• Cowden Disease (CD),Lhermitte-Duclos Disease (LDD),Bannayan-Zonana
Syndrom (BZS)
• In all 3 disorders, germline mutations in PTEN have been observed
• Still unclear why mutation in one gene leads to 3 related yet distinct
disorders
• An increased risk of breast cancer has been reported among men with
Cowden syndrome, with women with Cowden syndrome having an
approximate 75% risk for benign breast disease, as well as an over 50%
lifetime risk for breast cancer
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PTEN and PI-3 Kinase act as antagonists in
signaling
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PTEN (Phosphatase and Tensin homolog deleted on 
chromosome Ten)
• The PTEN protein can dephosphorylate phosphatidyl inositol 
3,4,5 trisphosphate and thereby antagonize the 
phosphatidylinositol-3-kinase signaling pathway. 
• PTEN negatively regulates intracellular levels of 
phosphatidylinositol-3,4,5-trisphosphate in cells and functions 
as a tumor suppressor by negatively regulating AKT/PKB 
signaling pathway. 
• PTEN may also inhibit cell migration through protein 
phosphatase activity on a threonine phosphate residue.
• Reference: Raftopoulou et al. Science 303, 1179-1181 (2004).
• it appears that one of the most relevant
consequences of the PTEN-defective phenotype is
the activation of the PI3K/Akt signaling pathway.
• Akt mediates multiple intracellular functions
pertaining to cell proliferation and apoptosis and has
been implicated in chemoresistance in colon, bladder
,ovarian and breast cancers
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Relationship of PTEN and Akt
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HONG-YAN Research 
• 146 female Chinese patients, who were diagnosed with breast cancer 
between 2003 and 2006
• Polymerase chain reaction-single strand conformation polymorphism 
(PCR-SSCP) analysis was performed to analyze mutations of  the 
PTEN gene
• The positive expression rate of  PTEN was 57.5% (84/146) in the 
breast cancer patients, but 100% in the normal breast tissues closely 
adjacent to the carcinoma
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L. Fulcher Research 
• MCF-7, MDA-MB-435 and MDA-MB-68 breast cancer cell lines 
• MCF-7 cell lines were transfected with the antisense PTEN 
constructs
• determine the relationship between PTEN status and response 
to inhibitors of  the PI3K/Akt kinase pathway
• PTEN expression strongly correlates with cellular response to 
exposure to PI3 kinase pathway inhibitors
12/25/2015 16
Summary
• The breast is a dynamic organ- undergoes cyclical proliferative changes throughout life under 
the influence of  hormones and growth factors- so may be likely to be more altered by 
environmental carcinogens
• Key function for ER and PR in breast cells. The same hormones that are important for breast 
growth during pregnancy are also important for breast cancer. 
• ER function in signaling through other growth factor receptor pathways becomes very 
important in cancer. Production of  estrogen through alternate sources keeps E supply ongoing 
in postmenopausal women.
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Summary
 PTEN is both a lipid and protein phosphatase
 Shown to be involved in pathways that involve apoptosis (or
anoikis), mobility, and cell adhesion
 PTEN is necessary for embryogenesis and may also control
tumor development in mice
 PTEN involved in 3 major genetic diseases with mutations in
one gene that cause similar yet distinct phenotypes
 PTEN mutated in many cancers but more needs to be learned
about the pathways involved to better understand how cancers
arise and to determine how to design new therapeutic
treatments
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TUMOR-SUPPRESSOR GENES -
Suggested reading
• B.H. Park and B. Vogelstein, In Holland-Frei Cancer 
Medicine 6th Edition, Part II, Section 1, 7. Tumor-
Suppressor Genes, 2003.
• Robert Weinberg, The Biology of Cancer, Chapter 7, 
Garland Press, 2007.
12/25/2015 19
• 1. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of  cell 
migration, spreading, and focal adhesions by tumor suppressor 
PTEN. Science. 1998;280:1614–1617. [PubMed]
• 2. Waite KA, Eng C. Protean PTEN: form and function. Am J Hum Genet. 2002;70:829–
844.[PMC free article] [PubMed]
• 3. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, 
Mao M, Zinner R, Hung MC, Steck P, Siminovitch K, Mills GB. The 
PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis 
and anoikis in breast cancer cells. Oncogene. 1999;18:7034–7045. [PubMed]
• 4. Weng LP, Brown JL, Eng C. PTEN coordinates (G1) arrest by down-regulating cyclin
D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase 
activity in a breast cancer model. Hum Mol Genet. 2001;10:599–604. [PubMed]
12/25/2015 20
• 5. Tamguney T, Stokoe D. New insights into PTEN. J Cell Sci. 2007;120:4071–
4079. [PubMed]
• 6. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, Liaw D, Caron S, 
Duboué B, Lin AY, Richardson AL, Bonnetblanc JM, Bressieux JM, Cabarrot-Moreau A, 
Chompret A, Demange L, Eeles RA, Yahanda AM, Fearon ER, Fricker JP, Gorlin RJ, 
Hodgson SV, Huson S, Lacombe D, Eng C, et al. Mutation spectrum and genotype-
phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma
syndromes with germline PTEN mutation. Hum Mol Genet. 1998;7:507–515. [PubMed]
• 7. Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H. PTEN methylation and 
expression in glioblastomas. Acta Neuropathol. 2003;106:479–485. [PubMed]
• 8. Freihoff D, Kempe A, Beste B, Wappenschmidt B, Kreyer E, Hayashi Y, Meindl A, 
Krebs D, Wiestler OD, von Deimling A, Schmutzler RK. Exclusion of  a major role for the 
PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer. 1999;79:754–758. [PMC 
free article] [PubMed]
12/25/2015 21
